Cinclus Pharma to participate in upcoming investor conferences
4 november, 08:00
Cinclus Pharma Holding AB (publ) today announced that management will participate in the following upcoming investor conferences during the month of November:
Stifel Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date and Time: November 11, 10:00-10:30 AM EDT
Location: New York
Webcast:https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/exG4NG6uekkGwknevs95UQ
Jefferies Global Healthcare Conference
Format: 1x1 meetings
Date and Time: November 17-19
Location: London
DNB Carnegie 6th Annual Nordic Healthcare Conference
Format: Group Presentation and 1x1 meetings
Date and Time: November 25, 15:10-15:30 CET
Location: Oslo
The webcast of the fireside chat at Stifel Healthcare Conferencewill be accessible on the Cinclus Pharma Presentations Website. A replay of the webcast will be available for approximately 90 days following the conference.
To request a meeting or for more details about the conferences, please reach out to your institutional contact.
For additional information, please contact:
Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com
Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikström@cincluspharma.com
About Cinclus Pharma
Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.
Attachments
Cinclus Pharma to participate in upcoming investor conferences
Ämnen i artikeln
Cinclus Pharma to participate in upcoming investor conferences
4 november, 08:00
Cinclus Pharma Holding AB (publ) today announced that management will participate in the following upcoming investor conferences during the month of November:
Stifel Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date and Time: November 11, 10:00-10:30 AM EDT
Location: New York
Webcast:https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/exG4NG6uekkGwknevs95UQ
Jefferies Global Healthcare Conference
Format: 1x1 meetings
Date and Time: November 17-19
Location: London
DNB Carnegie 6th Annual Nordic Healthcare Conference
Format: Group Presentation and 1x1 meetings
Date and Time: November 25, 15:10-15:30 CET
Location: Oslo
The webcast of the fireside chat at Stifel Healthcare Conferencewill be accessible on the Cinclus Pharma Presentations Website. A replay of the webcast will be available for approximately 90 days following the conference.
To request a meeting or for more details about the conferences, please reach out to your institutional contact.
For additional information, please contact:
Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com
Henrik Vikström, IR
Phone: +46 70 952 80 06
e-mail: henrik.vikström@cincluspharma.com
About Cinclus Pharma
Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. The first Phase III study commenced in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.
Attachments
Cinclus Pharma to participate in upcoming investor conferences
Ämnen i artikeln
Katastrofobligationer
Nibes rapport
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Katastrofobligationer
Nibes rapport
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Marknadsöversikt
1 DAG %
Senast
1 mån
